BBIO Stock Surges 76% And Pulls Both Alnylam Higher – Investor's Business Daily
Business News
- BBIO Stock Surges 76% And Pulls Both Alnylam Higher Investor’s Business Daily
- BridgeBio Surges After Heart Drug Succeeds in Pivotal Trial Yahoo Finance
- BridgeBio’s heart disease drug meets late-stage study goal, shares soar Reuters
- ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis TCTMD
- BridgeBio’s heart disease drug meets late-stage study goal, shares soar AOL
- View Full Coverage on Google News
Source: Business News